Scutellarin hydrate

• Catalog No.: SML0014
• M. F.: C21H18O12
• M. W.: 462.36042
• Purity: ≥98% (HPLC)
• Storage: desiccated

SYNONYMS

• IUPAC name: (2S,3S,4S,5R,6S)-6-{[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• IUPAC Traditional name: scutellarin
• Synonyms: 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl-β-D-glucopyranosiduronic acid hydrate; Scutellarein-7-O-β-D-glucuronide; 7-(β-D-Glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one hydrate; Breviscapin

PROPERTIES

• Empirical Formula (Hill Notation): C21H18O12 · xH2O
• Purity: ≥98% (HPLC)
• Apperance: yellow powder
• Solubility: DMSO: ≥10 mg/mL
• Storage Condition: desiccated
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Scutellarin is a flavonoid that exhibits a number of cardio- and neuro-protective effects. Scutellarin inhibits p38 activity, ERK phosphorylation, and TGF-β expression and fibrosis in a rat myocardial infarct model. In a cerebral ischemia-reperfusion model, the compound reduced infarct volume and neurological deficits by increasing eNOS expression while inhibiting the induction of iNOS.

Description (简体中文)

Biochem/physiol Actions
Scutellarin is a flavonoid that exhibits a number of cardio- and neuro-protective effects. Scutellarin inhibits p38 activity, ERK phosphorylation, and TGF-β expression and fibrosis in a rat myocardial infarct model. In a cerebral ischemia-reperfusion model, the compound reduced infarct volume and neurological deficits by increasing eNOS expression while inhibiting the induction of iNOS.